Streetbeat News

Stock Prices

JNJ

Johnson & Johnson announced promising results from the Phase 1b TRIMM-2 study, showing a 100% overall response rate in a weekly dosing arm for a combination therapy involving TALVEY and DARZALEX FASPRO in patients with relapsed or refractory multiple myeloma.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 12:02 pm

MLNK

MeridianLink's shares are trading lower following the announcement of a secondary public offering of 6,000,000 shares.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 12:01 pm

SG

Analysts have mixed ratings for Sweetgreen (NYSE:SG) with a positive shift in average price targets. The company shows strong revenue growth but faces profitability challenges.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 12:01 pm

ABR

Arbor Realty Trust (NYSE:ABR) has been analyzed by five analysts, showing a range of sentiments from somewhat bullish to somewhat bearish. The average 12-month price target has increased by 3.3% to $14.1. Analysts have adjusted their ratings and price targets, with some raising and others lowering their expectations. Despite a 9.7% decline in revenue over the past three months, Arbor Realty Trust maintains strong profitability with a net margin of 30.21% and a return on equity of 1.94%.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 12:00 pm

IONQ

IonQ shares rise following a $54.5 million contract with the US Air Force Research Lab.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 12:00 pm

BMBL

Analysts have shown a negative shift in sentiment towards Bumble (NASDAQ:BMBL), with a 34.15% decrease in the average 12-month price target. Despite Bumble's strong financial metrics, including a 3.42% revenue growth and a 10.2% net margin, analysts have lowered their price targets, reflecting concerns about the company's future performance.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 12:00 pm

WCC

WESCO Intl (NYSE:WCC) has been analyzed by six analysts, showing a range of sentiments from bullish to bearish. The average 12-month price target has decreased by 2.34% to $188. Analysts have adjusted their ratings and price targets, reflecting dynamic market conditions and company performance. WESCO faces revenue challenges and has a net margin below industry averages, but its ROE is strong, and it maintains a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 12:00 pm

SAVA

Cassava Sciences shares fell after the SEC charged the company and two former executives with making misleading claims about an Alzheimer's clinical trial.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 11:59 am

BGNE

BeiGene shares rose following the FDA Oncologic Drugs Advisory Committee's recognition of the favorable benefit-risk profile of PD-1 inhibitors, including BeiGene's TEVIMBRA.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 11:56 am

BMY

PRTC

The FDA has approved Bristol Myers Squibb's Cobenfy, a new class of treatment for schizophrenia, marking the first such approval in over 30 years. This approval, resulting from a deal with Karuna Therapeutics, introduces a novel approach by targeting specific brain receptors. The approval is based on successful clinical trials, and it triggers milestone payments to PureTech Health.

Portfolio Pulse from Vandana Singh

September 27, 2024 | 11:56 am